AMI Asset Management Corp Decreases Position in Kiniksa Pharmaceuticals International, plc $KNSA

AMI Asset Management Corp lessened its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 49.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,943 shares of the company’s stock after selling 21,173 shares during the quarter. AMI Asset Management Corp’s holdings in Kiniksa Pharmaceuticals International were worth $1,057,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of KNSA. EverSource Wealth Advisors LLC increased its position in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in shares of Kiniksa Pharmaceuticals International during the 2nd quarter worth $31,000. Smartleaf Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $36,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Up 5.4%

Shares of KNSA opened at $62.41 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $26.27 and a 12-month high of $63.77. The company has a market cap of $4.80 billion, a PE ratio of 69.34 and a beta of 0.12. The stock has a 50-day moving average price of $52.51 and a 200-day moving average price of $47.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.11 earnings per share. As a group, analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider John F. Paolini sold 58,424 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. This represents a 47.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the completion of the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at $22,398,541.44. The trade was a 52.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

KNSA has been the topic of a number of recent research reports. Canaccord Genuity Group upped their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Finally, Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $62.71.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.